157 related articles for article (PubMed ID: 34298618)
1. Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer.
Han CY; Patten DA; Kim SI; Lim JJ; Chan DW; Siu MKY; Han Y; Carmona E; Parks RJ; Lee C; Di LJ; Lu Z; Chan KKL; Ku JL; Macdonald EA; Vanderhyden BC; Mes-Masson AM; Ngan HYS; Cheung ANY; Song YS; Bast RC; Harper ME; Tsang BK
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298618
[TBL] [Abstract][Full Text] [Related]
2. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer.
Han CY; Patten DA; Lee SG; Parks RJ; Chan DW; Harper ME; Tsang BK
Mol Carcinog; 2019 Nov; 58(11):2161-2174. PubMed ID: 31486135
[TBL] [Abstract][Full Text] [Related]
3. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
[TBL] [Abstract][Full Text] [Related]
4. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
5. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate.
Chen Z; Zhang H; Lu W; Huang P
Biochim Biophys Acta; 2009 May; 1787(5):553-60. PubMed ID: 19285479
[TBL] [Abstract][Full Text] [Related]
6. Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin.
Gerber E; Asare-Werehene M; Reunov A; Burger D; Le T; Carmona E; Mes-Masson AM; Tsang BK
J Ovarian Res; 2023 Jan; 16(1):14. PubMed ID: 36642715
[TBL] [Abstract][Full Text] [Related]
7. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
8. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
9. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
10. Adrenomedullin induces cisplatin chemoresistance in ovarian cancer through reprogramming of glucose metabolism.
Dou L; Lu E; Tian D; Li F; Deng L; Zhang Y
J Transl Int Med; 2023 Jul; 11(2):169-177. PubMed ID: 37408575
[TBL] [Abstract][Full Text] [Related]
11. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
12. PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation.
Kobayashi N; Abedini M; Sakuragi N; Tsang BK
J Ovarian Res; 2013; 6():7. PubMed ID: 23351152
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
14. Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy.
Krasnov GS; Dmitriev AA; Lakunina VA; Kirpiy AA; Kudryavtseva AV
Expert Opin Ther Targets; 2013 Oct; 17(10):1221-33. PubMed ID: 23984984
[TBL] [Abstract][Full Text] [Related]
15. miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer.
Yu X; Zhang X; Wang G; Wang B; Ding Y; Zhao J; Liu H; Cui S
Cancer Cell Int; 2020 Nov; 20(1):534. PubMed ID: 33292230
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
17. Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro.
Wang K; Fan H; Chen Q; Ma G; Zhu M; Zhang X; Zhang Y; Yu J
Anticancer Drugs; 2015 Jan; 26(1):15-24. PubMed ID: 25229889
[TBL] [Abstract][Full Text] [Related]
18. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
[TBL] [Abstract][Full Text] [Related]
19. Cerulenin-induced apoptosis is mediated by disrupting the interaction between AIF and hexokinase II.
Jeong NY; Yoo YH
Int J Oncol; 2012 Jun; 40(6):1949-56. PubMed ID: 22426850
[TBL] [Abstract][Full Text] [Related]
20. FV-429 induces apoptosis and inhibits glycolysis by inhibiting Akt-mediated phosphorylation of hexokinase II in MDA-MB-231 cells.
Zhou Y; Lu N; Qiao C; Ni T; Li Z; Yu B; Guo Q; Wei L
Mol Carcinog; 2016 Sep; 55(9):1317-28. PubMed ID: 26258875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
